Home > Focus Areas > Type 2 Diabetes Connect > Post
  • Saved

3yr
Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know - PubMed

Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35266164/

doi: 10.1111/apt.16794. Online ahead of print. 1 Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2 Spirit Medical Communications, Manchester, UK. 3 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. doi: 10.1111/apt.16794. Online ahead of print.



Conclusions: These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further long-term phase III trials are warranted.

  • 3yr
    I have found GLP-1's extremely helpful in reducing patient's weight although it is not sustainable and patient followed up 6 months to 12 months thereafter did not continue to lose weight and may even start to regain
  • 3yr
    Key Points
    • Source: Alimentary Pharmacology and Therapeutics
    • Conclusion/Relevance: “These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further long-term phase III trials are warranted.”
    • GLP-TRAs improve clinical outcomes in terms of lowering glucose levels, as well as resulting in weight loss. They can also decrease cardiovascular events and improve liver enzymes.
    • Results from a phase II trial involving NASH patients demonstrated that liraglutide decreased metabolic dysfunction, insulin resistance, and lipotoxicity.
    • Liraglutide and semaglutide resulted in histological resolution of NASH in 40% to 60% of patients, according to trial results. Of note, no effect on fibrosis was not observed.
    • GLP-1RAs are associated with gastrointestinal and gallbladder-related adverse events. Gallbladder adverse events are likely secondary to weight loss. Meta-analyses do not suggest that GLP-TRAs lead to a higher risk of acute pancreatitis, pancreatic cancer, or other malignancies.
    • Currently, an ongoing phase III trial in about 1200 patients with non-cirrhotic NASH will assess the efficacy and safety of weekly semaglutide compared with that of placebo during a study period of 240 weeks.

You might also like